

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

213966US0PCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/926199

INTERNATIONAL APPLICATION NO.

PCT/JP00/01663

INTERNATIONAL FILING DATE

17 March 2000

PRIORITY DATE CLAIMED

24 March 1999

TITLE OF INVENTION

METHOD FOR QUANTITATING CHOLESTEROL

APPLICANT(S) FOR DO/EO/US

YAMAMOTO Mitsuaki et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Request for Consideration of Documents Cited in International Search Report/Notice of Priority
PCT/IB/304/Drawings (4 Sheets)/PCT/IB/308

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.492 (a) (1) - (5)) : 09/926199		INTERNATIONAL APPLICATION NO. PCT/JP00/01663		ATTORNEY'S DOCKET NUMBER 213966US0PCT	
---	--	--	--	---	--

24. The following fees are submitted:..

				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/>	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$1000.00			
<input checked="" type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$860.00			
<input type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$710.00			
<input type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$690.00			
<input type="checkbox"/>	International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$100.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$860.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).			\$0.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	30 - 20 =	10	x \$18.00	\$180.00	
Independent claims	6 - 3 =	3	x \$80.00	\$240.00	
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,280.00	
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$1,280.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$1,280.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				\$0.00	
TOTAL FEES ENCLOSED =				\$1,280.00	
				Amount to be: refunded	\$
				charged	\$

a. ☒ A check in the amount of **\$1,280.00** to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **15-0030** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:



22850
Sunder Sachar
Registration No. 34,423

Sunder Sachar

SIGNATURE

Norman F. Oblon

NAME

24,618

REGISTRATION NUMBER

9-24-01

DATE

09/926199

213966US-0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :

MITSUAKI YAMAMOTO ET AL. :

SERIAL NO: NEW U.S. PCT APPLN. : ATTN: APPLICATION BRANCH
(Based on PCT/JP00/01663)

FILED: HERewith :

FOR: METHOD FOR QUANTITATING
CHOLESTEROLPRELIMINARY AMENDMENTASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE SPECIFICATION

Please replace the last paragraph on page 17, lines 23 and 24 through page 18, line 6, with the following paragraph:

Specifically, 300 μ l of a first reagent, a 50 mM MES buffer (pH 6.5) containing 0.005% (40 μ M) digitonin, was added to 3 μ l of the samples. After 5 minutes, 100 μ l of a cholesterol determination reagent (a second reagent), which is a 50 mM phosphate buffer (pH 6.5) containing 1% Emulgen B-66, 1 U/ml cholesterol esterase, 1 U/ml cholesterol oxidase, 5 U/ml peroxidase, 0.04% disulfobutyl-m-toluidine, and 0.004% 4-aminoantipyrine, was added.

IN THE CLAIMS

Please amend the claims as shown on the marked-up copy following this amendment to read as follows.

7. (Amended) The method according to claim 1, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a saponin.

9. (Amended) The method according to claim 7, wherein the saponin is digitonin or tomatine.

10. (Amended) The method according to claim 1, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a polyene.

12. (Amended) The method according to claim 10, wherein the polyene is selected from the group consisting of nystatin, filipin, pimacyllin, pentamycin, trichomycin, fungichromin, perimycin, amphotericin, etoluscomycin, primycin, and candigin.

13. (Amended) The method according to claim 1, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a peptide.

15. (Amended) The method according to claim 1, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a lectin.

REMARKS

Claims 1-30 are active in the present application. Claims 7, 9, 10, 12 and 15 have been amended to remove multiple dependencies. The specification has been amended to correct a typographical error. No new matter is added. Action on the merits and allowance of the claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518



22850

(703) 413-3000
NFO/DJP/smi

I:\atty\SUKOS\213966US-pr.wpd

Marked-Up Copy

Serial No:

Amendment Filed on:

09-24-01

IN THE

SPECIFICATION

Please replace the last paragraph on page 17, lines 23 and 24 through page 18, line 6, with the following paragraph:

--Specifically, 300 μ l of a first reagent, a 50 mM MES buffer (pH 6.5) containing 0.005% (40 [μ m] μ M) digitonin, was added to 3 μ l of the samples. After 5 minutes, 100 μ l of a cholesterol determination reagent (a second reagent), which is a 50 mM phosphate buffer (pH 6.5) containing 1% Emulgen B-66, 1 U/ml cholesterol esterase, 1 U/ml cholesterol oxidase, 5 U/ml peroxidase, 0.04% disulfobutyl-m-toluidine, and 0.004% 4-aminoantipyrine, was added.--

IN THE CLAIMS

Please amend the claims as follows.

--7. (Amended) The method according to claim 1 [or claim 6], wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a saponin.

9. (Amended) The method according to claim 7 [or claim 8], wherein the saponin is digitonin or tomatine.

10. (Amended) The method according to claim 1 [or claim 6], wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a polyene.

12. (Amended) The method according to claim 10 [or claim 11], wherein the polyene is selected from the group consisting of nystatin, filipin, pimacyllin, pentamycin, trichomycin, fungichromin, perimycin, amphotericin, etoluscomycin, primycin, and candigin.

13. (Amended) The method according to claim 1 [or claim 6], wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a peptide.

15. (Amended) The method according to claim 1 [or claim 6], wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a lectin.--

09/926199

DESCRIPTION

METHOD FOR QUANTITATING CHOLESTEROL

TECHNICAL FIELD

The present invention relates to a method of quantitative
5 determination of cholesterol which can discriminatively and
quantitatively determine the amount of cholesterol present in
specific lipoprotein fractions efficiently by a simple
procedure using a small amount of sample.

BACKGROUND ART

Lipids such as cholesterol are combined with an apoprotein
and form a lipoprotein in blood serum. Lipoproteins are grouped
into chylomicron, very low density lipoprotein (VLDL), low
density lipoprotein (LDL), and high density lipoprotein (HDL)
15 according to their physical properties. Among these
lipoproteins, LDL is one of the substances which causes
arteriosclerosis, whereas HDL is known to exhibit an
anti-arteriosclerosis effect.

From the viewpoint of epidemiology, the cholesterol value
20 in LDL has a positive correlation with the frequency of
arteriosclerosis occurrence, whereas the cholesterol value in
HDL is known to have a reverse correlation with the frequency
of arteriosclerosis occurrence. Nowadays, cholesterol values
in HDL and LDL are frequently measured for an objective of
25 prevention and diagnosis of ischemic heart diseases. As a method
of measuring cholesterol in HDL and LDL, a method of measuring
cholesterols after separating HDL and LDL each from other

lipoproteins by ultracentrifugation, a method of separating HDL and LDL by electrophoresis, staining lipids, and measuring the intensity of color are known, for example.

However, none of these known methods are used in an everyday practice due to problems such as complicated procedures, incapability of treating a great number of samples, and the like.

A method of measuring cholesterols in HDL widely used in the field of clinical tests is a precipitation method which comprises adding a precipitant to a sample to cause lipoproteins other than HDL to aggregate, removing the aggregate by centrifugation, and measuring cholesterols in the supernatant liquid which contains only HDL. Although this method is simple and easy as compared with ultracentrifugation methods and electrophoretic analysis, the method not only requires a comparatively large amount of sample due to the separating procedure by the addition of a precipitant, but also involves a great risk of analytical error. Therefore, it has been impossible to completely automate the entire analytical process.

A method of discriminating enzymatic determination of cholesterols in HDL has been studied. For example, an enzymatic reaction in the presence of a bile salt and a nonionic surfactant is known (Japanese Patent Application Laid-open No. 126498/1988). This method utilizes the nature of the enzymatic reaction of proceeding in proportion to the LDL cholesterol concentration at the initial stage, but in proportion to the

HDL cholesterol concentration at the later stage. However, the analytical accuracy of the method is questioned because it is impossible to completely separate the reaction of cholesterol in HDL and the reaction of cholesterol in other lipoproteins.

5 Another method known in the art comprises previously aggregating lipoproteins other than HDL, enzymatically reacting only cholesterol in HDL, inactivating the enzyme and, at the same time, redissolving the aggregate, and measuring the absorbance (Japanese Patent Application Laid-open No.

10 242110/1994). However, this method can be applied only to limited automated analyzers because of requirement of reagent addition at least three times. Thus, the generality of the method is limited. The method is also unsatisfactory from the viewpoint of damage to the analytical instrument and disposal of reagents because redissolution of precipitate requires the
15 use of high concentration of salts and the like.

Japanese Patent No. 2600065 discloses a method of using a precipitation reagent for lipoproteins other than HDL used in a conventional precipitation method and a commonly used
20 reagent for the measurement of cholesterol to measure cholesterol in HDL which have not been precipitated. A specific example disclosed is a combination of a modifying enzyme and α -cyclodextrin sulfate.

The other methods include a method of using a surfactant
25 to reduce the interference of precipitants (Japanese Patent Application Laid-open No. 116996/1996), a method of using antibodies for precipitating lipoproteins other than HDL instead

of the conventional precipitation reagent (Japanese Patent Application Laid-open No. 96637/1997), a method of using carrageenan (Japanese Patent Application Laid-open No. 121895/1997), and a method of using a sugar compound (Japanese Patent Application Laid-open No. 301636/1995). These methods have problems such as formation of turbidity due to aggregation even in the case where normal serum is mixed, the requirement of aggregating lipoproteins other than HDL (LDL, VLDL, etc.) of which measurement is unnecessary, and the like. As a method of measuring cholesterol in LDL widely accepted in the field of clinical tests, the method of Friedewald (Clinical Chemistry, vol. 18, pp. 459-502 (1972)) is known. According to this method, the amount of LDL cholesterol is determined by using the amounts of total cholesterol, HDL cholesterol, and triglyceride determined by enzymatic methods. This method, however, cannot be applied when the concentration of triglyceride is more than 400 mg/dl.

An object of the present invention, therefore, is to provide a method of quantitative determination of cholesterol in the specific fraction which does not require a pretreatment such as centrifugation, can be carried out efficiently by a simple procedure, and can be applied to various types of automated analyzers.

DISCLOSURE OF THE INVENTION

As a result of extensive studies, the inventors of the present invention have found that if the reaction of a

cholesterol determination enzymatic reagent is carried out in the presence of a compound possessing relatively strong affinity with one of the lipoproteins in a sample and of a surfactant exhibiting relatively strong action on other lipoproteins in the sample, it is possible to provide a significant difference between the reaction of the cholesterol present in a specific lipoprotein in the sample and the reaction of the cholesterol included in the other lipoproteins, whereby cholesterol in the target lipoprotein can be discriminated and determined with a substantially sufficient accuracy.

Specifically, the present invention provides a method of selectively quantitating cholesterol, comprising determining the amount of cholesterol in a measuring lipoprotein fraction in a sample in the presence of a compound having a relatively strong affinity with non-measuring lipoproteins in the sample, a surfactant exhibiting a relatively strong action on the measuring lipoproteins, and a cholesterol determination reagent.

The present invention further provides a method of selectively determining the amount of cholesterol comprising preferentially reacting the cholesterol present in non-measuring lipoproteins in a sample in the presence of a compound having a relatively strong affinity with the measuring lipoprotein in the sample, a surfactant exhibiting a relatively strong action on the non-measuring lipoproteins, and a cholesterol determination reagent, and determining the amount of cholesterol in the remaining measuring lipoprotein.

Figure 3 is a chart showing the correlation between the method of Example 6 and a conventional precipitation method.

Figure 4 is a chart showing the correlation between the method of Example 7 and a conventional precipitation method.

BEST MODE FOR CARRYING OUT THE INVENTION

In the present invention, prior to the reaction between cholesterol in lipoproteins and a cholesterol determination reagent, a compound having a relatively strong affinity with one of the lipoproteins in the sample (hereinafter referred to as "selective affinity agent") and a surfactant exhibiting a relatively strong action on the other lipoproteins (hereinafter referred to as "selective activator") must be added.

Of these, the selective affinity agent exhibits a mutual action with lipoproteins for which reaction or determination is not desired, and inhibits or suppresses the reaction between those lipoproteins and a cholesterol determination reagent. On the other hand, the selective activator exhibits a strong action on lipoproteins to be reacted or determined when the lipoproteins to be reacted or determined and the lipoproteins for which reaction or determination is not desired are present in the same system, and accelerates the reaction between those lipoproteins to be reacted or determined and the cholesterol determination reagent.

The affinity of the selective affinity agent with one lipoprotein and the action of the selective activator on the other lipoproteins in the present invention must be relatively

strong, but need not be absolutely strong. The reason is because relative errors, which may be significant when only one of them is used, can be reduced to a level at which no problem occurs in actual practice when both are used.

5 As the selective affinity agent used in the present invention, a compound exhibiting affinity with the components forming a lipoprotein surface layer of the lipoproteins for which reaction or determination is not desired can be given. Cholesterols, phospholipids, and apoproteins and the like can
10 be given as the components forming a lipoprotein surface layer.

As examples of such a selective affinity agent, saponins, polyenes, cholesterol derivatives, peptides, lectins, phospholipid derivatives, and the like can be given. As saponins exhibiting affinity with cholesterols, for example, digitonin,
15 tomatine, and the like can be given;

as polyenes, nystatin, filipin, pimacillyn, pentamycin, trichomycin, fungichromin, perimycin, amphotericin, etoluscomycin, primycin, candigin, and the like can be given;

as cholesterol derivatives,
20 [N-[2-(cholesterylcarboxyamino)ethyl]carbamoylmethyl]-pullulan (abbreviated to "Chol-AECM-Pullulan") and the like can be given;

as peptides, bacitracin, polymyxin, suzucasylin, gramicidin, and the like can be given;

25 as lectins, concanavalin A, castor lectin, peanuts lectin, and the like can be given; and

as phospholipid derivatives, L- α -phosphatidyl glycerol

dipalmitoyl and the like can be given.

A reaction mixture may become turbid when a sample containing lipoproteins is mixed with some of the above-mentioned selective affinity agents according to the conditions of reagent composition. This may be due to production of aggregate of lipoproteins. However, aggregation of non-measuring lipoproteins is not indispensable in the present invention.

For example, no turbidity is observed when digitonin (a saponin derivative), Chol-AECM-pullulan (a cholesterol derivative), filipin (a polyene compound), L- α -phosphatidyl glycerol dipalmitoyl (a phospholipid derivative), or the like is mixed with a sample containing lipoproteins under conditions in which the effect of the present invention can be exhibited.

It is important for the selective affinity agent of the present invention to adsorb or bind with the components forming lipoprotein surface layers in a manner in which the reaction between cholesterol in lipoproteins and an enzyme is inhibited or suppressed. It is absolutely unnecessary for the lipoproteins to aggregate.

These selective affinity agents may be used either individually or in combination of two or more. Although not specifically limited, the amount of selective affinity agents used differs according to the compounds in the range usually from about 1 nM to 0.1 M ($1 \times 10^{-7}\%$ to 10%), and preferably from 10 nM to 0.1 M ($1 \times 10^{-6}\%$ to 1%). An organic solvent such as alcohol, a surfactant, and a phospholipid can be used to dissolve these

compounds. These solvents and the like may be used either individually or in combination of two or more. The amount used differs according to the type of compound to be dissolved, but is not specifically limited.

5 On the other hand, either an ionic or nonionic selective activator may be used inasmuch as such a selective activator exhibits an action on lipoproteins to be reacted or determined to a different degree in which the selective activator exhibits an action on the lipoproteins for which reaction or
10 determination is not desired. Polyoxyethylene (10) octylphenyl ether, polyoxyethylene higher alcohol ether, polyoxyethylene alkylene phenyl ether, polyoxyethylene alkylene tribenzyl phenyl ether, and the like can be given as examples.

Particularly preferable selective activators are

15 polyoxyethylene alkylene phenyl ether and polyoxyethylene alkylene tribenzylphenyl ether, which are known as surfactants exhibiting a strong reactivity with specific lipoproteins when reacted alone with these lipoproteins (Japanese Patent Application Laid-open No. 313200/1997). As examples of
20 commercially available products of these selective activators Triton X-100, Emulgen 709, Emulgen A-60, Emulgen B-66, heptane sulfonic acid, octane sulfonic acid, and the like can be given.

These selective activators may be used either individually or in combinations of two or more. Although not specifically
25 limited, the amount of selective activators used differs according to the compounds in the range from 0.0001%-5%, and preferably from 0.001%-5%.

These selective affinity agents and selective activators can be added to a sample serum either separately or concurrently as a mixture. Any known enzymatic methods can be used for the determination of cholesterols. Examples include a method of using cholesterol esterase and cholesterol oxidase in combination as enzyme reagents, a method of using cholesterol esterase and cholesterol dehydrogenase in combination, and the like. Of these, a method using cholesterol esterase and cholesterol oxidase in combination is preferable.

There are no specific limitations to the method of finally detecting cholesterols after the addition of these cholesterol determination enzyme reagents. For example, an absorbance analysis additionally using a combination of a peroxidase and a coloring substance, a method of directly detecting coenzyme and hydrogen peroxide, and the like can be given.

Preferred specific embodiments of the present invention are as follows:

(1) A method of selectively determining the amount of cholesterol in a measuring lipoprotein in a sample in the presence of a compound having a relatively strong affinity with non-measuring lipoproteins in the sample, a surfactant exhibiting a relatively strong action on the measuring lipoproteins, and a cholesterol determination reagent.

(2) A method of selectively determining the amount of cholesterol comprising preferentially reacting the cholesterols present in non-measuring lipoproteins in a sample in the presence of a compound having a relatively strong

affinity with the measuring lipoprotein in the sample, a
surfactant exhibiting a relatively strong action on the
non-measuring lipoproteins, and a cholesterol determination
reagent, and determining the amount of cholesterol in the
5 remaining measuring lipoprotein.

(3) A method of determining the concentration of
cholesterols in various lipoproteins comprising
preferentially reacting the cholesterols present in a second
measuring lipoprotein in a sample in the presence of a compound
10 having a relatively strong affinity with a first measuring
lipoprotein in the sample, a surfactant exhibiting a relatively
stronger action on the second lipoprotein than the first
lipoprotein, and a cholesterol determination reagent,
determining the amount of cholesterol in the remaining first
15 measuring lipoprotein, and determining the concentration of
cholesterols in each lipoprotein from the resultant amount of
cholesterol in the remaining first measuring lipoprotein and
the total cholesterol concentration.

In practicing the above methods, a reagent for
20 quantitative determination of cholesterols comprising,
separately or as a mixture, a selective affinity agent, a
selective activator, and a cholesterol determination reagent
is conveniently used. The reagents for quantitative
determination of cholesterols used in the above methods are as
25 follows:

Reagent used in the above method (1):

A reagent for quantitative determination of cholesterols

comprising, separately or as a mixture, a compound having a relatively strong affinity with non-measuring lipoproteins in the sample, a surfactant exhibiting a relatively strong action on measuring lipoproteins, and a cholesterol determination reagent.

Reagent used in the above method (2):

A reagent for quantitative determination of cholesterols comprising, separately or as a mixture, a compound having a relatively strong affinity with measuring lipoproteins in the sample, a surfactant exhibiting a relatively strong action on non-measuring lipoproteins, and a cholesterol determination reagent.

Reagent used in the above method (3):

A reagent for quantitative determination of cholesterols comprising, separately or as a mixture, a compound having a relatively strong affinity with a first measuring lipoprotein in the sample, a surfactant exhibiting a stronger action on a second measuring lipoprotein than on the first measuring lipoprotein, and a cholesterol determination reagent.

A commonly used buffer solution such as a phosphate buffer, a Good's buffer, and the like may be added to the above reagents for the quantitative determination of cholesterols. There are no specific limitations to the pH of a solution in which these reagents for quantitative determination are dissolved to the extent that the enzyme reagents are not affected. In addition, an inorganic salt such as sodium chloride, additives such as albumin used for stabilizing enzyme activity, a salt of divalent

metal, a compound acting as a preservative, and the like may also be used.

Cholesterols can be quantitatively determined efficiently by a simple procedure without requiring a pretreatment such as centrifugation by using the method of the present invention described above. In addition, because the method allows specific determination by a simple method using a small amount of sample, the method can be applied to various types of automatic analyzers. The method is thus extremely useful in the field of clinical diagnosis.

EXAMPLES

The present invention will be described in more detail by examples, which should not be construed as limiting the present invention.

Example 1

Samples containing lipoproteins were prepared according to the following method given in the preparation of samples. The amount of cholesterol in each lipoprotein fractions was determined by the following method given in the measuring method to compare the reactivity. The results are shown in Table 1. (Preparation of samples)

Samples were prepared by fractionating human serum into VLDL, LDL, and HDL by ultracentrifugation.

(Measuring method)

300 μ l of a first reagent, a 50 mM phosphate buffer (pH

6.5) containing 0.005% digitonin, was added to 3 μ l of the sample. After 5 minutes, 100 μ l of a cholesterol determination reagent (a second reagent), which is a 50 mM phosphate buffer (pH 6.5) containing 0.2% Triton X-100, 1 U/ml cholesterol esterase, 1 U/ml cholesterol oxidase, 5 U/ml peroxidase, 0.04% disulfobutyl-m-toluidine, and 0.004% 4-aminoantipyrine, was added.

Absorbance was measured at 600 nm and 700 nm on the sample immediately before and five minutes after the addition of the cholesterol determination reagent, to compare the difference in the reactivity among the lipoprotein fractions (Two point method). The above procedure was carried out using Hitachi 7150 automated analyzer (manufactured by Hitachi Ltd.).

(Results)

Table 1

Sample	No addition of selective affinity agent	Addition of 0.005% digitonin
HDL fraction	0.104 (100%)	0.099 (95%)
LDL fraction	0.315 (100%)	0.218 (69%)
VLDL fraction	0.267 (100%)	0.136 (51%)

(a numerical value shows absorbance)

It can be seen from Table 1 that cholesterols in HDL can be preferentially reacted with enzymes over the cholesterols in LDL and the cholesterols in VLDL if digitonin is present.

Example 2

The amount of cholesterol was determined and compared in the same manner as in Example 1, except that 0.005% Chol-AECM-Pullulan was used instead of digitonin as a first reagent and the surfactant (Triton X-100) in the second reagent was replaced with 1% Emulgen B-66. The results are shown in Table 2.

(Results)

Table 2

Sample	No addition of selective affinity agent	Addition of 0.005% Chol-AECM-Pullulan
HDL fraction	0.133 (100%)	0.132 (99%)
LDL fraction	0.028 (100%)	0.019 (67%)
VLDL fraction	0.025 (100%)	0.013 (50%)

(a numerical value shows absorbance)

It can be seen from Table 2 that cholesterol in HDL can be preferentially reacted with an enzyme over the cholesterol in LDL and the cholesterol in VLDL if Chol-AECM-Pullulan is present.

Example 3

Samples were prepared in the same manner as in Example 1. The amount of cholesterol in each lipoprotein fractions was determined by the same method as in Example 1 using reagents of the composition shown below to compare the reactivity. The results are shown in Table 3.

(Reagents used)

First reagent:

50 mM PIPES buffer solution (pH 6.5) containing 5 mM L- α -

phosphatidylglycerol dipalmitoyl and 0.5% Triton X-100

Cholesterol determination reagent:

50 mM PIPES buffer solution (pH 6.5) containing 1 U/ml cholesterol esterase, 1 U/ml cholesterol oxidase, 5 U/ml peroxidase, 0.04% disulfobutyl-m-toluidine, and 0.004% 4-aminoantipyrine.

(Results)

Table 3

Sample	No addition of selective affinity agent	Addition of 5 mM L- α -phosphatidylglycerol dipalmitoyl
HDL fraction	111.8 (100%)	107.2 (96%)
LDL fraction	328.6 (100%)	200.4 (61%)
VLDL fraction	161.9 (100%)	59.6 (37%)

(a numerical value shows absorbance)

It can be seen from Table 3 that cholesterol in HDL can be preferentially reacted with an enzyme over the cholesterol in LDL and the cholesterol in VLDL if L- α -phosphatidylglycerol dipalmitoyl is present.

Example 4

Cholesterol in HDL in 25 serum samples containing lipoproteins were determined by the method of the present invention method and the conventional precipitation method, and the measurement value of these methods was compared.

Specifically, 300 μ l of a first reagent, a 50 mM MES buffer (pH 6.5) containing 0.005% (40 μ m) digitonin, was added to 3 μ l

of the samples. After 5 minutes, 100 μ l of a cholesterol determination reagent (a second reagent), which is a 50 mM phosphate buffer (pH 6.5) containing 1% Emulgen B-66, 1 U/ml cholesterol esterase, 1 U/ml cholesterol oxidase, 5 U/ml peroxidase, 0.04% disulfobutyl-m-toluidine, and 0.004% 4-aminoantipyrine, was added.

Absorbance was measured at 600 nm and 700 nm on the sample immediately before and five minutes after the addition of the cholesterol determination reagent, to determine the HDL cholesterol concentration from the difference in the absorbance values (Two point method). A control serum with a known concentration was used as a calibration standard. The above procedure was carried out using Hitachi 7150 automated analyzer (manufactured by Hitachi Ltd.).

On the other hand, cholesterol determination in HDL by the precipitation method (the comparative method) was carried out as follows. 200 μ l of an aqueous solution containing 0.3% of sodium phosphotungstate and 2% of magnesium chloride was mixed with 200 μ l of the sample. The mixture was centrifuged at 3000 r.p.m. for 10 minutes. 50 μ l of the supernatant solution was mixed with 3 ml of a cholesterol determination reagent, which is a 100 mM MES buffer solution (pH 6.5) containing 1% Triton X-100, 1 U/ml cholesterol esterase, 1 U/ml cholesterol oxidase, 5 U/ml peroxidase, 0.04% disulfobutyl-m-toluidine, and 0.004% 4-aminoantipyrine. The mixture was incubated for 10 minutes at 37°C to measure the absorbance at 600 nm, based on which cholesterol in HDL were determined. The results are shown in

Table 4 and Figure 1.

(Results)

Table 4

Sample No.	Precipitation method (mg/dl)	Invention method (mg/dl)
1	99.6	103.6
2	91.8	95.2
3	81.6	86.6
4	78.6	80.1
5	71.9	74.4
6	70.3	71.9
7	67.6	72.4
8	70.1	72.1
9	66.6	70.1
10	64.5	67.4
11	64.5	67.4
12	60.9	63.2
13	60.3	62.6
14	54.6	55.0
15	55.0	56.9
16	50.7	51.0
17	50.9	52.7
18	49.2	51.2
19	47.0	48.7
20	45.7	47.4
21	41.0	41.8
22	37.9	40.2
23	39.6	40.3
24	94.8	98.4
25	88.5	93.3
Correlation coefficient		0.999
Inclination		1.052
Intercept		-0.921

5

As can be seen from Table 4 and Figure 1, the method of the present invention shows a very good correlation with the conventional precipitation method in spite of the simple procedure.

Example 5

Cholesterols in HDL were determined by the method of the present invention and the conventional precipitation method using 25 serum samples containing lipoproteins. The method of the present invention used in Example 4 was followed, except that digitonin in the first reagent was replaced by 0.1 % polymyxin B and 0.005% concanavalin A. The results are shown in Table 5 and Figure 2.

(Results)

Table 5

Sample No.	Precipitation method (mg/dl)	Invention method (mg/dl)
1	113.8	112.4
2	100.3	104.0
3	96.9	98.9
4	91.6	97.3
5	86.5	89.1
6	83.9	87.2
7	83.7	87.4
8	79.0	82.0
9	78.2	79.6
10	74.7	78.3
11	72.5	74.0
12	72.3	71.9
13	70.4	73.2
14	66.5	68.4
15	65.9	68.7
16	62.7	64.8
17	58.0	59.7
18	52.5	54.4
19	49.7	52.1
20	45.6	47.8
21	42.3	45.9
22	39.0	40.7
23	39.8	40.8
24	38.2	38.4
25	34.2	36.7
Correlation coefficient		0.998
Inclination		1.007
Intercept		1.775

As can be seen from Table 5 and Figure 2, the method of the present invention shows a very good correlation with the conventional precipitation method in spite of the simple procedure.

Example 6

Cholesterols in HDL were determined by the method of the present invention and the conventional precipitation method using 25 serum samples containing lipoproteins. The method of the present invention used in Example 4 was followed, except
5 that the digitonin in the first reagent was replaced by 0.005% (76 μ M) filipin. The results are shown in Table 6 and Figure 3.

(Results)

10

Table 6

Sample No.	Precipitation method (mg/dl)	Invention method (mg/dl)
1	113.8	120.7
2	100.3	111.7
3	96.9	105.6
4	91.6	102.0
5	86.5	90.2
6	83.9	93.0
7	83.7	90.5
8	79.0	80.0
9	78.2	80.7
10	74.7	80.9
11	72.5	80.1
12	72.3	72.9
13	70.4	73.1
14	66.5	67.9
15	65.9	67.0
16	62.7	65.3
17	58.0	59.4
18	52.5	58.0
19	49.7	55.8
20	45.6	48.0
21	42.3	45.6
22	39.0	41.2
23	39.8	41.7
24	38.2	40.7
25	34.2	41.1
Correlation coefficient		0.993
Inclination		1.075
Intercept		-0.473

As can be seen from Table 6 and Figure 3, the method of the present invention shows a very good correlation with the conventional precipitation method in spite of the simple procedure.

Example 7

Cholesterols in HDL were determined by the method of the

present invention and the conventional precipitation method using 30 serum samples containing lipoproteins.

260 μ l of a cholesterol determination reagent containing a selective affinity agent, consisting of a 50 mM PIPES buffer solution (pH 6.5) containing 0.0075% (60 μ M) digitonin, 0.25% Emulgen B-66, 0.25 U/ml cholesterol esterase, 0.25 U/ml cholesterol oxidase, 1.25 U/ml peroxidase, 0.01% disulfobutyl-m-toluidine, and 0.005% 4-aminoantipyrine, was added to 2 μ l of the sample.

Absorbance was measured at 600 nm and 700 nm on the sample at two minutes and seven minutes after the addition of the cholesterol determination reagent containing a selective affinity agent, to determine the HDL cholesterol from the difference in the absorbance values (Two point method). A control serum with a known concentration was used as a calibration standard. The above procedure was carried out using Hitachi 7170 automated analyzer (manufactured by Hitachi Ltd.).

The same method as in Example 3 was used for the cholesterol determination in HDL according to the precipitation method (the comparative method). The results are shown in Table 7 and Figure 4.

(Results)

Table 7

Sample No.	Precipitation method (mg/dl)	Invention method (mg/dl)
1	103.2	103.7
2	91.8	91.6
3	89.4	91.6
4	83.4	88.6
5	82.7	84.2
6	80.6	82.3
7	78.9	79.7
8	77.0	77.6
9	76.2	79.1
10	74.9	76.4
11	76.1	72.9
12	77.6	79.4
13	67.5	68.6
14	65.7	69.0
15	69.0	71.9
16	66.5	65.4
17	62.3	64.0
18	61.3	63.2
19	57.3	56.8
20	53.9	55.4
21	54.9	54.5
22	52.1	52.4
23	47.4	47.1
24	46.4	44.6
25	41.7	42.3
26	39.1	42.1
27	38.6	38.6
28	32.3	33.5
29	31.8	33.2
30	26.5	32.4
Correlation coefficient		0.995
Inclination		0.995
Intercept		1.485

As can be seen from Table 7 and Figure 4, the method of the present invention shows a very good correlation with the conventional precipitation method in spite of the simple procedure.

CLAIMS

1. A method of selectively quantitating cholesterol, comprising determining the amount of cholesterol in a measuring lipoprotein fraction in a sample in the presence of a compound having a relatively strong affinity with non-measuring lipoproteins in the sample, a surfactant exhibiting a relatively strong action on the measuring lipoproteins, and a cholesterol determination reagent.

2. The method according to claim 1, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample has an affinity with a component composing a lipoprotein surface layer of those lipoproteins.

3. The method according to claim 2, wherein the component composing a lipoprotein surface layer of the non-measuring lipoproteins is cholesterol.

4. The method according to claim 2, wherein the component composing a lipoprotein surface layer of the non-measuring lipoproteins is phospholipid.

5. The method according to claim 2, wherein the component composing a lipoprotein surface layer of the non-measuring lipoproteins is apoprotein.

6. The method according to claim 1, wherein the compound

having a relatively strong affinity with the non-measuring lipoproteins in the sample is at least one compound selected from the group consisting of saponins, polyenes, cholesterol derivatives, peptides, lectins, and phospholipid derivatives.

5

7. The method according to claim 1 or claim 6, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a saponin.

10

8. The method according to claim 7, wherein the saponin is a steroid saponin.

9. The method according to claim 7 or claim 8, wherein the saponin is digitonin or tomatine.

15

10. The method according to claim 1 or claim 6, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a polyene.

20

11. The method according to claim 10, wherein the polyene is an antibiotic.

25

12. The method according to claim 10 or claim 11, wherein the polyene is selected from the group consisting of nystatin, filipin, pimacyllin, pentamycin, trichomycin, fungichromin, perimycin, amphotericin, etoluscomycin, primycin, and candigin.

13. The method according to claim 1 or claim 6, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a peptide.

5

14. The method according to claim 13, wherein the peptide is bacitracin, polymyxin, suzucasylin, or gramicidin.

15. The method according to claim 1 or claim 6, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a lectin.

16. The method according to claim 15, wherein the lectin is concanavalin A, castor lectin, or peanuts lectin.

17. The method according to claim 1, wherein the compound having a relatively strong affinity with the non-measuring lipoproteins in the sample is a steroid-binding compound.

18. A reagent for quantitative determination of cholesterol comprising, separately or as a mixture, a compound having a relatively strong affinity with non-measuring lipoproteins in the sample, a surfactant exhibiting a relatively strong action on measuring lipoproteins, and a cholesterol determination reagent.

19. A method of selectively quantitating cholesterol

comprising preferentially reacting the cholesterol present in non-measuring lipoproteins in a sample in the presence of a compound having a relatively strong affinity with the measuring lipoprotein in the sample, a surfactant exhibiting a relatively strong action on the non-measuring lipoproteins, and a cholesterol determination reagent, and determining the amount of cholesterol in the remaining measuring lipoprotein.

20. The method according to claim 19, wherein the compound having a relatively strong affinity with the measuring lipoproteins in the sample has an affinity with the components composing a lipoprotein surface layer of those lipoproteins.

21. The method according to claim 20, wherein the components composing a lipoprotein surface layer of the measuring lipoproteins are cholesterol.

22. The method according to claim 20, wherein the component composing a lipoprotein surface layer of the measuring lipoproteins is phospholipid.

23. The method according to claim 20, wherein the component composing a lipoprotein surface layer of the measuring lipoproteins is apoprotein.

24. A reagent for quantitative determination of cholesterol comprising, separately or as a mixture, a compound

having a relatively strong affinity with measuring lipoproteins in the sample, a surfactant exhibiting a relatively strong action on non-measuring lipoproteins, and a cholesterol determination reagent.

5

25. A method of determining the concentration of cholesterol in each lipoproteins comprising preferentially reacting the cholesterol present in a second measuring lipoprotein in a sample in the presence of a compound having a relatively strong affinity with a first measuring lipoprotein in the sample, a surfactant exhibiting a relatively stronger action on the second lipoprotein than the first lipoprotein, and a cholesterol determination reagent, determining the amount of cholesterol in the remaining first measuring lipoprotein, and determining the concentration of cholesterol in each lipoprotein from the resultant amount of cholesterol in the remaining first measuring lipoprotein and the total cholesterol concentration.

20

26. The method according to claim 25, wherein the compound having a relatively strong affinity with the first measuring lipoproteins in the sample has an affinity with the components composing a lipoprotein surface layer of those lipoproteins.

25

27. The method according to claim 26, wherein the components composing a lipoprotein surface layer of the first measuring lipoproteins are cholesterol.


28. The method according to claim 26, wherein the component composing a lipoprotein surface layer of the first measuring lipoproteins is phospholipid.


5

29. The method according to claim 26, wherein the component composing a lipoprotein surface layer of the first measuring lipoproteins is apoprotein.

30. A reagent for quantitative determination of
cholesterols comprising, separately or as a mixture, a compound
having a relatively strong affinity with a first measuring
lipoprotein in the sample, a surfactant exhibiting a stronger
action on a second measuring lipoprotein than on the first
measuring lipoprotein, and a cholesterol determination
reagent.

09/926199

**FIG. 1**

**FIG. 2**

09/926199





FIG. 3

**FIG. 4**